Evidence map›Paper›PMID 33586970›Full record

ArticleJournal of the American Society for Mass Spectrometry2021

Investigation of D76N β

Owen Cornwell, James R Ault, Nicholas J Bond, Sheena E Radford, Alison E Ashcroft

Open access · hybridAbstract read
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Owen CornwellBiopharmaceuticals R & D, AstraZeneca, Granta Park, Cambridge CB21 6GP, U.K.
James R AultAstbury Centre for Structural Molecular Biology & School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, U.K.
Nicholas J BondBiopharmaceuticals R & D, AstraZeneca, Granta Park, Cambridge CB21 6GP, U.K.
Sheena E RadfordAstbury Centre for Structural Molecular Biology & School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, U.K.ORCID http://orcid.org/0000-0002-3079-8039
Alison E AshcroftAstbury Centre for Structural Molecular Biology & School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, U.K.ORCID http://orcid.org/0000-0002-1676-123X
University of Leeds · GBAstraZeneca (Australia) · AU

Funding

Biotechnology and Biological Sciences Research Council BB/E012558/1Wellcome Trust 204963Wellcome Trust 204963/Z/16/Z
6 · The paper itself

Abstract

NMR studies and X-ray crystallography have shown that the structures of the 99-residue amyloidogenic protein β

Indexed as

Amino Acid Substitutionbeta 2-MicroglobulinHumansHydrogen Deuterium Exchange-Mass SpectrometryProtein ConformationProtein FootprintingB2M protein, humanbeta 2-MicroglobulinamyloidD76NFPOPHDXprotein conformationstructural mass spectrometryβ2m

Identifiers

PMID33586970
PMCPMC9282677
OpenAlexW3130358898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.